David W. Pritchard

David W. Pritchard has served as KaloBios Pharmaceuticals, Inc.’s President and Chief Executive Officer since August 2006. Mr. Pritchard has more than 25 years of experience in general management, business development and financial management within the biopharmaceutical industry. Prior to joining KaloBios, he held the position of Chief Business Officer at Rinat Neuroscience Corporation, where he managed the acquisition of Rinat by Pfizer in 2006. Prior to that, he was Chief Financial Officer at Matrix Pharmaceuticals and managed the sale of the company to Chiron Corporation — now Novartis. Between 1992 and 2000, Mr. Pritchard served as Vice President, Business Development and Chief Financial Officer of Metabolex, Inc., where he completed three rounds of financing and negotiated four worldwide corporate alliances with major pharmaceutical companies. He started his biotechnology career at Triton Biosciences, Inc., as one of the founding managers, where he held various positions, including heading up sales and marketing, commercial development and cancer diagnostics, and ultimately managed the sale of Triton — predominantly to Schering AG, now Bayer. Mr. Pritchard holds a Bachelor of Science in chemical engineering from Cornell University and a Master of Business Administration from Stanford University.